Clinical Trial Detail

NCT ID NCT02631733
Title Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

stomach cancer

ovarian cancer

cervical cancer

neuroendocrine tumor

triple-receptor negative breast cancer

lung small cell carcinoma

Therapies

Irinotecan + Veliparib

Age Groups: adult

No variant requirements are available.